Opus Genetics, Inc.

https://www.opusgtx.com

Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company dedicated to developing gene therapies to restore vision and prevent blindness in patients suffering from inherited retinal diseases (IRDs) and other retinal and refractive disorders. The company's mission is to design therapies that address the underlying genetic causes of severe retinal disorders, aiming to deliver durable vision improvement for patients. Headquartered in Durham, North Carolina, Opus Genetics focuses on advancing treatments for conditions with significant unmet medical needs.

The company's pipeline includes seven adeno-associated virus (AAV)-based gene therapy programs. Lead candidates include OPGx-LCA5 for Leber congenital amaurosis type 5 and OPGx-BEST1 for BEST1-related retinal degeneration, with additional programs targeting genes such as RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a small-molecule therapy, which is approved for pharmacologically induced mydriasis and is being developed for potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery.

Led by CEO George Magrath, Opus Genetics has recently achieved several notable milestones. In April 2026, the company secured a strategic financing agreement with Oberland Capital Management LLC, providing access to up to $155 million in non-dilutive funding to accelerate its pipeline. The company was recognized on Fast Company's World's Most Innovative Companies 2026 list in the Biotech category in March 2026. Additionally, Opus Genetics reported promising early results from its Phase 1/2 trial of OPGx-BEST1 in March 2026, demonstrating vision improvements and a favorable safety profile. The FDA has also accepted a supplemental New Drug Application for phentolamine ophthalmic solution 0.75% for presbyopia, with a PDUFA goal date of October 17, 2026.

Latest updates

Opus Genetics to Present Data Across Pipeline at Key Ophthalmology Conferences

Event summary

  • Opus Genetics will present data from its LCA5 and BEST1 gene therapy programs at ARVO, Retina Therapeutics Innovation Summit, ASGCT, and Retina World Congress in May 2026.
  • The company will present preliminary Phase 1b/2a data for OPGx-BEST1 and preclinical data for OPGx-RHO at ARVO in Denver, CO, May 3–7, 2026.
  • Opus Genetics is also advancing a small-molecule therapy, Phentolamine Ophthalmic Solution, with a supplemental new drug application under review for presbyopia.
  • The company’s pipeline includes seven AAV-based programs targeting various inherited retinal diseases (IRDs).

The big picture

Opus Genetics' conference participation highlights the ongoing race to develop gene therapies for inherited retinal diseases, a market with significant unmet need and potential for high returns. The company’s focus on both gene therapy and small molecule approaches reflects a strategy to address a broader range of retinal disorders. Success in these clinical trials and regulatory approvals will be key to validating the company’s platform and attracting further investment in the competitive gene therapy space.

What we're watching

Clinical Efficacy
The upcoming presentations will be critical in assessing the clinical efficacy of OPGx-BEST1, particularly given the preliminary nature of the Phase 1b/2a data; investor sentiment will likely hinge on these findings.
Regulatory Pathway
The ongoing review of the supplemental new drug application for Phentolamine Ophthalmic Solution will influence investor confidence in Opus Genetics’ broader regulatory strategy and ability to expand its product portfolio.
Pipeline Breadth
The company’s commitment to expanding its AAV-based pipeline beyond LCA5 and BEST1 will determine its long-term competitive positioning within the increasingly crowded gene therapy landscape.

Opus Genetics Data Highlights Potential for Presbyopia Drug, Niche Vision Treatment

Event summary

  • Opus Genetics will present data at the 2026 ASCRS Annual Meeting, including full results from Phase 3 VEGA-3 trial for phentolamine ophthalmic solution 0.75% for presbyopia.
  • A post-hoc analysis of the MIRA-2 trial evaluating RYZUMVI®’s optical impact will also be presented.
  • Data from the LYNX-2 trial, assessing phentolamine ophthalmic solution for visual disturbances in post-refractive surgery patients, will be presented again.
  • Viatris is providing funding for an educational symposium on presbyopia correction, complementing Opus Genetics’ scientific program.

The big picture

Opus Genetics is attempting to capitalize on the large and growing market for presbyopia correction, currently addressed primarily by glasses and contact lenses. The Phase 3 data presented at ASCRS represents a key inflection point for the company, as it seeks to establish phentolamine ophthalmic solution as a viable alternative. The partnership with Viatris provides a crucial commercialization pathway, but also introduces dependency risk.

What we're watching

Commercialization
The success of Viatris’ commercialization efforts for phentolamine ophthalmic solution will be critical for Opus Genetics’ revenue generation, given the licensing agreement.
Regulatory Risk
The supplemental new drug application for presbyopia faces regulatory hurdles, and approval timelines will significantly impact market entry and revenue projections.
Market Adoption
The rate at which clinicians adopt phentolamine ophthalmic solution for presbyopia, and the willingness of patients to embrace a pharmacological approach, will determine the drug’s overall market penetration.

Opus Genetics Secures $155M Financing to Accelerate Gene Therapy Pipeline

Event summary

  • Opus Genetics secured a strategic financing agreement with Oberland Capital, including up to $155 million in non-dilutive funding and a $5 million equity investment.
  • The financing extends Opus Genetics’ cash runway into 2029, supporting clinical trials for OPGx-LCA5 and OPGx-BEST1 and enabling the initiation of three additional gene therapy programs into clinical testing within the next year.
  • Oberland Capital’s investment includes a $35 million initial tranche, with additional tranches available based on milestones and mutual agreement, and a convertible note structure.
  • The deal also includes a $5 million equity investment at $4.48 per share, alongside a stock purchase agreement for 1.1 million shares.

The big picture

This financing underscores the growing investor interest in gene therapy for inherited retinal diseases, a market with significant unmet need. Oberland Capital’s $3.2 billion AUM and specialized focus on healthcare financing signals confidence in Opus Genetics’ platform and pipeline. The non-dilutive nature of a significant portion of the funding is a positive, but the convertible note structure introduces potential future equity dilution if milestones aren't met.

What we're watching

Execution Risk
The ability of Opus Genetics to achieve the milestones triggering the additional tranches of funding will be critical to maintaining financial flexibility and avoiding potential dilution.
Clinical Outcomes
The topline results from the Phase 1/2 trial for OPGx-BEST1, expected mid-2026, will heavily influence investor sentiment and the likelihood of further funding tranches.
Regulatory Landscape
The timing and outcome of the supplemental new drug application for Phentolamine Ophthalmic Solution will impact the company’s near-term revenue and potentially influence the valuation of its gene therapy programs.

Opus Genetics Earns Fast Company Innovation Nod Amidst Gene Therapy Scrutiny

Event summary

  • Opus Genetics (Nasdaq: IRD) was recognized as one of Fast Company’s Most Innovative Companies of 2026 in the Biotech category.
  • The recognition highlights the company’s patient-centered approach to developing gene therapies for inherited retinal diseases (IRDs).
  • Opus Genetics’ pipeline includes OPGx-BEST1 and OPGx-LCA5, targeting ultra-rare conditions with significant unmet need.
  • The company is also advancing Phentolamine Ophthalmic Solution 0.75% for presbyopia and low contrast conditions, with an ongoing Phase 3 trial.

The big picture

The Fast Company recognition underscores the growing interest in gene therapies for rare diseases, a market segment attracting significant investment. However, the high cost of development and the inherent risks associated with gene therapy delivery create a challenging landscape. Opus Genetics’ patient-centric approach, while laudable, introduces complexities in defining clinical endpoints and securing regulatory approval, potentially impacting the timeline for commercialization.

What we're watching

Clinical Efficacy
The long-term clinical efficacy of OPGx-BEST1 and OPGx-LCA5 will be critical to sustaining investor enthusiasm, particularly given the challenges of gene therapy delivery and durability.
Regulatory Pathway
The FDA’s review of Phentolamine Ophthalmic Solution will set a precedent for the company’s broader gene therapy applications, potentially influencing timelines and approval criteria.
Patient Adoption
The company’s patient-centric development model will be tested as therapies reach market; adoption rates will depend on demonstrating tangible benefits and addressing patient concerns about gene therapy risks.

Opus Genetics Secures Funding, Advances Pipeline Amidst Regulatory Tailwinds

Event summary

  • Opus Genetics reported $45.1 million in cash and cash equivalents as of December 31, 2025, bolstered by a recent $25 million private placement.
  • Early clinical data from the BEST1 program showed initial safety and functional vision improvement in the first patient, with full cohort data expected mid-2026.
  • The FDA has set a PDUFA date of October 17, 2026, for Phentolamine Ophthalmic Solution 0.75% to treat presbyopia.
  • Funding from Abu Dhabi’s Healthcare Research and Innovation Fund will support clinical trials for OPGx-MERTK, targeting retinitis pigmentosa.

The big picture

Opus Genetics operates in a high-growth, capital-intensive gene therapy sector focused on rare inherited retinal diseases. The reauthorization of the Rare Pediatric Disease Priority Review Voucher program is a significant tailwind, incentivizing investment in this niche area. However, the company's success hinges on demonstrating clinical efficacy, navigating regulatory hurdles, and maintaining a sustainable financial trajectory amidst intense competition and the inherent risks of early-stage drug development.

What we're watching

Clinical Efficacy
The full Cohort 1 data for OPGx-BEST1, expected mid-year, will be critical in assessing the long-term efficacy and safety profile, potentially influencing future trial design and regulatory pathways.
Regulatory Risk
The FDA’s review of Phentolamine Ophthalmic Solution, with its October 2026 PDUFA date, presents a near-term catalyst, but potential delays or requests for additional data could impact the company’s valuation.
Funding Sustainability
While the recent funding extends the cash runway into 2028, Opus Genetics will need to demonstrate continued progress and potentially secure additional financing to support its expanding pipeline and clinical trials.

Opus Genetics Schedules Investor Roadshow Amidst Clinical Trial Scrutiny

Event summary

  • Opus Genetics (IRD) will present at three investor conferences in March 2026: Leerink Global Healthcare Conference (March 10), Citizens Life Sciences Conference (March 11), and RBC Capital Markets Global Ophthalmology Conference (March 25).
  • The conferences will include webcasts accessible via the company’s investor relations website.
  • Opus Genetics’ pipeline includes seven AAV-based gene therapy programs targeting inherited retinal diseases (IRDs).
  • The company is also developing Phentolamine Ophthalmic Solution 0.75% for potential indications beyond pharmacologically induced mydriasis.

The big picture

Opus Genetics' investor roadshow signals an effort to maintain market confidence as gene therapy companies face increased regulatory scrutiny and pricing pressures. The company’s pipeline, while promising, requires substantial investment and carries inherent clinical and regulatory risks. The upcoming presentations will be a key indicator of investor sentiment and the company’s ability to navigate these challenges.

What we're watching

Clinical Progress
The presentations will likely focus on interim data from ongoing clinical trials; investor reception will hinge on the perceived efficacy and safety of OPGx-LCA5 and OPGx-BEST1.
Financial Runway
Given the capital-intensive nature of gene therapy development, the company's cash burn rate and ability to secure additional funding will be closely scrutinized during these presentations.
Competitive Landscape
The presentations will need to clearly articulate Opus Genetics’ differentiated approach and competitive advantages within the increasingly crowded gene therapy space targeting IRDs.

Opus Genetics Gene Therapy Shows Early Promise in BEST1-Related Retinal Disease Trial

Event summary

  • Opus Genetics presented initial data from a Phase 1/2 trial of OPGx-BEST1 gene therapy at the Macula Society meeting.
  • The sentinel participant, a 63-year-old female, showed no serious adverse events or dose-limiting toxicities at three months.
  • Early data indicate a 12-letter gain in Best Corrected Visual Acuity (BCVA) and a 23% reduction in central subfield thickness (CST) in the treated eye.
  • Full cohort data for the Phase 1/2 trial is expected in mid-year 2026.

The big picture

Opus Genetics' OPGx-BEST1 program addresses a significant unmet need in the treatment of rare inherited retinal diseases, a market attracting increasing investment and innovation. The early positive safety and efficacy data are a crucial step, but the success of the program hinges on demonstrating durable benefit and navigating the complexities of gene therapy manufacturing and delivery. The lack of existing treatments for BEST1-related diseases creates an opportunity, but also increases scrutiny of clinical outcomes.

What we're watching

Efficacy Signals
The observed BCVA and CST improvements, while preliminary, will need to be consistently replicated across the full cohort to validate OPGx-BEST1's therapeutic potential.
Regulatory Pathway
Given the lack of approved treatments for BEST1-related retinal diseases, the FDA's regulatory flexibility and potential for accelerated approval will be a key factor in the program's timeline.
Competitive Landscape
As gene therapy for inherited retinal diseases gains traction, the emergence of competing therapies and platforms could impact OPGx-BEST1’s market share and pricing strategy.

Opus Genetics Secures FDA Acceptance for Presbyopia Treatment

Event summary

  • Opus Genetics received FDA acceptance for a supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% to treat presbyopia.
  • The FDA has assigned a PDUFA goal date of October 17, 2026, for review.
  • The sNDA is supported by data from Phase 3 clinical trials (VEGA-2 and VEGA-3) demonstrating positive efficacy and safety.
  • Phentolamine ophthalmic solution 0.75% is already approved for treating pharmacologically-induced mydriasis.
  • Viatris holds exclusive commercialization rights for the product in the U.S. under a global licensing agreement.

The big picture

Opus Genetics is attempting to expand the use of an existing drug, Ryzumvi, into a significantly larger market – presbyopia, which affects a vast portion of the adult population. This strategy leverages an already approved formulation, reducing development risk but also potentially limiting pricing flexibility. The success of this sNDA hinges on Viatris’s ability to effectively market and distribute the product, competing against both existing corrective lenses and emerging surgical solutions.

What we're watching

Regulatory Risk
The October PDUFA date presents a near-term catalyst, but approval is not guaranteed, and any FDA concerns could impact the stock.
Commercial Execution
Viatris's commercial capabilities will be crucial for successful market penetration, given the large but fragmented presbyopia market.
Competitive Landscape
The emergence of non-pharmacological presbyopia treatments (e.g., corneal inlays, lens replacement) could limit phentolamine’s market share and pricing power.

Opus Genetics Lands $25 Million Private Placement to Fuel Gene Therapy Pipeline

Event summary

  • Opus Genetics secured a $25 million private placement of Series B Non-Voting Convertible Preferred Stock.
  • The financing was led by Adage Capital Management, with participation from Trails Edge Capital Partners and Marshall Wace.
  • Proceeds will be used to advance clinical programs, working capital, and general corporate purposes.
  • The company projects a year-end 2025 pro forma cash balance of $70 million, extending its runway into the first half of 2028.
  • The offering is expected to close on February 18, 2026, contingent on shareholder approval for increased authorized shares.

The big picture

This private placement demonstrates ongoing investor interest in Opus Genetics' gene therapy programs targeting inherited retinal diseases, a market with significant unmet need. The sizable round ($25 million) suggests a degree of confidence in the company's pipeline, but also highlights the capital intensity of gene therapy development. The use of convertible preferred stock, while common in biotech, introduces a layer of complexity regarding future dilution and shareholder equity.

What we're watching

Conversion Risk
The successful conversion of the preferred stock into common stock hinges on shareholder approval, which introduces a potential hurdle for future equity raises and could impact the company's capital structure.
Clinical Execution
The company’s ability to effectively utilize the new capital to advance its clinical programs, particularly OPGx-LCA5 and OPGx-BEST1, will be critical in demonstrating value and attracting further investment.
Registration Timeline
The timeline for the SEC registration of the shares underlying the private placement will influence the liquidity of these holdings and the company’s ability to access public markets in the near term.

Opus Genetics to Present Clinical Data, Manufacturing Strategy at Key Ophthalmology Conferences

Event summary

  • Opus Genetics leadership will present at the Collaborative Community on Ophthalmic Innovation (CCOI) in Hong Kong, February 3-4, 2026.
  • The company will engage with the ophthalmology community at the Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong, February 5-8, 2026.
  • Chief Technology Officer Chris Ernst will discuss scalable viral vector manufacturing models at Advanced Therapies Week Conference in San Diego, February 11, 2026.
  • Preliminary results from a Phase 1b/2a clinical study of OPGx-BEST1 will be presented at The Macula Society Annual Meeting in San Diego, February 27, 2026.

The big picture

Opus Genetics' conference participation highlights the ongoing race to develop gene therapies for inherited retinal diseases, a market with significant unmet need but also substantial technical and regulatory hurdles. The company's focus on both clinical data and manufacturing scalability indicates a dual strategy of demonstrating efficacy and preparing for potential commercialization. The company’s pipeline includes seven AAV-based programs, suggesting a broad commitment to gene therapy solutions.

What we're watching

Clinical Progress
The presentation of preliminary data for OPGx-BEST1 at The Macula Society will be critical in assessing the viability of the program and its potential to address BEST1-related retinal degeneration, a relatively niche but unmet need.
Manufacturing Scale
The focus on scalable viral vector manufacturing suggests Opus Genetics is anticipating increased demand for its therapies, but the success of this strategy will hinge on cost-effectiveness and regulatory approval.
Geographic Expansion
Participation in the APAO Congress signals an intent to expand Opus Genetics’ presence in the Asia-Pacific region, requiring careful navigation of local regulatory landscapes and market access challenges.

Opus Genetics Advances Pipeline, Eyes 2026 Data Readouts

Event summary

  • Opus Genetics reported $50 million in cash reserves as of January 2026, following a $23 million registered direct offering.
  • The company anticipates clinical data from its BEST1 program and plans to accelerate its LCA5 program into pivotal testing in 2026.
  • A supplemental New Drug Application (sNDA) has been submitted for a partnered presbyopia treatment, with a regulatory decision expected by year-end 2026.
  • Opus Genetics is exploring regulatory designations, including Rare Pediatric Disease, which could lead to Priority Review Vouchers (PRVs).

The big picture

Opus Genetics is operating in a competitive gene therapy landscape, where success depends on demonstrating efficacy and safety in rare, often pediatric, indications. The company's focus on ophthalmic applications, coupled with the potential for Priority Review Vouchers, positions it to benefit from the increasing demand for innovative treatments for inherited retinal diseases. However, the high cost of gene therapy development and the regulatory hurdles involved create significant risks.

What we're watching

Clinical Execution
The success of the BEST1 program hinges on the data presented at the Macula Society; any setbacks could significantly impact investor confidence and future development timelines.
Regulatory Risk
The FDA’s decision on the sNDA for the presbyopia treatment will be a key catalyst, and a rejection could delay commercialization and impact the company’s financial projections.
Capital Needs
While the current cash position extends into 2H 2027, Opus Genetics will likely need to secure additional funding through partnerships or equity offerings to support the Phase 3 trial for LCA5 and advance its pre-clinical pipeline.
CID: 246